Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists dig into past cases of rare lymphoma to find clues for better care

NCT ID NCT06781359

Knowledge-focused Sponsor: Fondazione Italiana Linfomi - ETS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 20, 2026 · Updated 2 times

Summary

This study will review the medical records of 200 people diagnosed with plasmablastic lymphoma, a rare blood cancer, between 2000 and 2022. Researchers want to learn more about the disease's features, treatments used, and what affects survival. No new treatments are given; the goal is to gather information to guide future care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2025

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients (Age ≥ 18 years old) with diagnosis of plasmablastic lymphoma (Histologically confirmed) between Jan 1st 2000, and Dec 31st 2022

Ages

15 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of plasmablastic lymphoma (PBL) between Jan 1st 2000, and Dec 31st 2022 * Histologically confirmed plasmablastic lymphoma (PBL) diagnosis according to local pathological report * Age \> 18 years old * Availability of complete medical records * Availability of histopathological material requested by the study Exclusion Criteria: * Any other histology than PBL * Lack of complete medical records * Lack of histopathological material requested by the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Plasmablastic lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

plasmablastic lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Plasmablastic lymphoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    18 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • A.O. S. Croce e Carle, S.C. di Ematologia e Trapianto di Midollo Osseo

    RECRUITING

    Cuneo, Italy

  • A.O.U. Città della Salute e della Scienza di Torino, Ematologia Universitaria

    NOT_YET_RECRUITING

    Torino, Italy

  • A.O.U. Città della Salute e della Scienza di Torino, S.C. Ematologia

    RECRUITING

    Torino, Italy

  • AOU Maggiore della Caritа di Novara, SCDU Ematologia

    ACTIVE_NOT_RECRUITING

    Novara, Italy

  • ASST -Fatebenefratelli - Polo Luigi Sacco Oncologia

    RECRUITING

    Milan, Italy

  • ASST Grande Ospedale Metropolitano Niguarda, SC Ematologia

    RECRUITING

    Milan, Italy

  • ASST Spedali Civili di Brescia, Ematologia

    ACTIVE_NOT_RECRUITING

    Brescia, Italy

  • Azienda Ospedaliera Universitaria Careggi, Unità funzionale di Ematologia

    RECRUITING

    Florence, Italy

  • Azienda Ospedaliera Universitaria Sant' Andrea, Ematologia

    RECRUITING

    Roma, Italy

  • Azienda Ospedaliera Universitaria di Padova, Ematologia

    NOT_YET_RECRUITING

    Padova, Italy

  • Azienda Ospedaliero Universitaria Senese, U.O.C. Ematologia

    RECRUITING

    Siena, Italy

  • Azienda Unitа Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova, Ematologia

    RECRUITING

    Reggio Emilia, Italy

  • Fondazione IRCCS San Gerardo dei Tintori, Ematologia

    RECRUITING

    Monza, Italy

  • IRCCS Centro di Riferimento Oncologico di Aviano, Divisione di Oncologia e dei Tumori immuno-correlati

    RECRUITING

    Aviano, PN, Italy

  • Istituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia

    ACTIVE_NOT_RECRUITING

    Milan, Italy

  • Ospedale C.e G. Mazzoni, U.O.C. di Ematologia

    RECRUITING

    Ascoli Piceno, Italy

  • Ospedale Maggiore Policlinico - Fondazione IRCCS Ca' Granda, Ematologia

    ACTIVE_NOT_RECRUITING

    Milan, Italy

  • Ospedale S. Chiara, S.S. di Ematologia

    RECRUITING

    Trento, Italy

  • Policlinico Umberto I - Università La Sapienza, Istituto Ematologia, Dipartimento di Medicina Traslazionale e di Precisione

    RECRUITING

    Roma, Italy

  • Presidio ospedaliero A. Tortora, U.O. Onco-ematologia

    NOT_YET_RECRUITING

    Pagani, Italy

  • ULSS 8 Berica - Ospedale S. Bortolo, Ematologia

    RECRUITING

    Vicenza, Italy

  • ULSS2 Marca Trevigiana, Ospedale Ca' Foncello, S.C di Ematologia

    ACTIVE_NOT_RECRUITING

    Treviso, Italy

  • Universitа Cattolica S. Cuore, Ematologia

    NOT_YET_RECRUITING

    Roma, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.